Sarah K Fritschi
Overview
Explore the profile of Sarah K Fritschi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uhlmann R, Rother C, Rasmussen J, Schelle J, Bergmann C, Ullrich Gavilanes E, et al.
Nat Neurosci
. 2020 Nov;
23(12):1580-1588.
PMID: 33199898
Amyloid-β (Aβ) deposits are a relatively late consequence of Aβ aggregation in Alzheimer's disease. When pathogenic Aβ seeds begin to form, propagate and spread is not known, nor are they...
2.
Schelle J, Wegenast-Braun B, Fritschi S, Kaeser S, Jahrling N, Eicke D, et al.
Ann Neurol
. 2019 Jul;
86(4):561-571.
PMID: 31359452
Objective: Clinical trials targeting β-amyloid peptides (Aβ) for Alzheimer disease (AD) failed for arguable reasons that include selecting the wrong stages of AD pathophysiology or Aβ being the wrong target....
3.
Holth J, Fritschi S, Wang C, Pedersen N, Cirrito J, Mahan T, et al.
Science
. 2019 Jan;
363(6429):880-884.
PMID: 30679382
The sleep-wake cycle regulates interstitial fluid (ISF) and cerebrospinal fluid (CSF) levels of β-amyloid (Aβ) that accumulates in Alzheimer's disease (AD). Furthermore, chronic sleep deprivation (SD) increases Aβ plaques. However,...
4.
Ye L, Rasmussen J, Kaeser S, Marzesco A, Obermuller U, Mahler J, et al.
EMBO Rep
. 2017 Jul;
18(9):1536-1544.
PMID: 28701326
Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease (AD) at different stages of the long preclinical and clinical phases. Given that the...
5.
Ye L, Fritschi S, Schelle J, Obermuller U, Degenhardt K, Kaeser S, et al.
Nat Neurosci
. 2015 Sep;
18(11):1559-61.
PMID: 26352792
Cerebral β-amyloidosis is induced by inoculation of Aβ seeds into APP transgenic mice, but not into App(-/-) (APP null) mice. We found that brain extracts from APP null mice that...
6.
Ye L, Hamaguchi T, Fritschi S, Eisele Y, Obermuller U, Jucker M, et al.
Brain Pathol
. 2015 Feb;
25(6):743-52.
PMID: 25677332
An important early event in the pathogenesis of Alzheimer's disease (AD) is the aberrant polymerization and extracellular accumulation of amyloid-β peptide (Aβ). In young transgenic mice expressing the human Aβ-precursor...
7.
Schweighauser M, Bacioglu M, Fritschi S, Shimshek D, Kahle P, Eisele Y, et al.
Acta Neuropathol
. 2014 Nov;
129(1):157-9.
PMID: 25367384
No abstract available.
8.
Fritschi S, Langer F, Kaeser S, Maia L, Portelius E, Pinotsi D, et al.
Brain
. 2014 Sep;
137(Pt 11):2909-2915.
PMID: 25212850
The soluble fraction of brain samples from patients with Alzheimer's disease contains highly biologically active amyloid-β seeds. In this study, we sought to assess the potency of soluble amyloid-β seeds...
9.
Fritschi S, Cintron A, Ye L, Mahler J, Buhler A, Baumann F, et al.
Acta Neuropathol
. 2014 Sep;
128(4):477-84.
PMID: 25193240
Cerebral β-amyloidosis can be exogenously induced by the intracerebral injection of brain extracts containing aggregated β-amyloid (Aβ) into young, pre-depositing Aβ precursor protein- (APP) transgenic mice. Previous work has shown...
10.
Eisele Y, Fritschi S, Hamaguchi T, Obermuller U, Fuger P, Skodras A, et al.
J Neurosci
. 2014 Aug;
34(31):10264-73.
PMID: 25080588
Deposition of aggregated amyloid-β (Aβ) peptide in brain is an early event and hallmark pathology of Alzheimer's disease and cerebral Aβ angiopathy. Experimental evidence supports the concept that Aβ multimers...